Hemangiosarcoma (HSA) is an aggressive disease that is fairly common in the dog. The authors evaluated a doxorubicin, dacarbazine, and vincristine (DAV) combination protocol in dogs with nonresectable stage II and stage III HSA. Twenty-four dogs were enrolled in this prospective, phase 2 study. Doxorubicin and dacarbazine were administered on day 1 while vincristine was administered on days 8 and 15. The protocol was repeated every 21 days for a maximum of six cycles or until disease progression. Toxicity and efficacy were assessed by clinical and laboratory evaluation and by questionnaires completed by the owners. Of the 24 included dogs, 19 were evaluable for response. The response rate (including five complete responses and four partial responses) was 47.4%. Median time to tumor progression was 101 days and median overall survival was 125 days. Significant toxicities were noted, including 41 high-grade hematologic and 12 high-grade gastrointestinal toxic events. Five dogs discontinued treatment due to chemotherapy-related toxicities, but no treatment-related deaths occurred. Multivariate analysis identified patient age (relative risk [RR], 2.3, P=0.049) to be negatively associated with time to progression whereas dacarbazine dose reductions (RR, 0.06, P=0.031) were positively associated with time to progression. Dacarbazine dose reduction was the sole factor positively associated with overall survival (RR, 0.28, P=0.015). In conclusion, the DAV combination appears to offer clinical responses and may prolong survival in dogs with advanced-stage HSA.
Skip Nav Destination
Article navigation
May/June 2011
Original Studies|
May 01 2011
Treatment with DAV for Advanced-Stage Hemangiosarcoma in Dogs
Nikolaos G. Dervisis, DVM, DACVIM (Oncology), PhD;
Center for Comparative Oncology, Michigan State University, East Lansing, MI.
Correspondence: [email protected] (N.D.)
Search for other works by this author on:
Pedro A. Dominguez, DVM, DACVIM (Oncology), DACVR (Radiation Oncology);
Pedro A. Dominguez, DVM, DACVIM (Oncology), DACVR (Radiation Oncology)
*
Center for Comparative Oncology, Michigan State University, East Lansing, MI.
Search for other works by this author on:
Rebecca G. Newman, DVM, DACVIM (Oncology);
Rebecca G. Newman, DVM, DACVIM (Oncology)
†
Center for Comparative Oncology, Michigan State University, East Lansing, MI.
Search for other works by this author on:
Casey D. Cadile, DVM, DACVIM (Oncology);
Casey D. Cadile, DVM, DACVIM (Oncology)
§
Center for Comparative Oncology, Michigan State University, East Lansing, MI.
Search for other works by this author on:
Barbara E. Kitchell, DVM, DACVIM (Oncology, Internal Medicine), PhD
Barbara E. Kitchell, DVM, DACVIM (Oncology, Internal Medicine), PhD
Center for Comparative Oncology, Michigan State University, East Lansing, MI.
Search for other works by this author on:
J Am Anim Hosp Assoc (2011) 47 (3): 170–178.
Citation
Nikolaos G. Dervisis, Pedro A. Dominguez, Rebecca G. Newman, Casey D. Cadile, Barbara E. Kitchell; Treatment with DAV for Advanced-Stage Hemangiosarcoma in Dogs. J Am Anim Hosp Assoc 1 May 2011; 47 (3): 170–178. doi: https://doi.org/10.5326/JAAHA-MS-5525
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionCiting articles via
Long-Term Survival of Primary Intracranial Histiocytic Sarcoma Through Surgical Resection and Low-Dose CCNU
Kyosuke Hidari, DVM, Yuya Nakamoto, DVM, PhD, James K. Chambers, DVM, PhD, Kazuyuki Uchida, DVM, PhD, Isao Mori, DVM, Miwa Nakamoto, DVM
Microfilaria in the Urine of a Dog with Concurrent Urinary Bladder Sarcoma
Nicole Schlette, DVM, Erin Burton, DVM, MS, DACVP, Amber Harris, DVM, DACVIM (Internal Medicine), Kendall Langsten, DVM, DACVP, Erik Olson, DVM, PhD, DACVP, Daniel Heinrich, DVM, DACVP
Chronic Myelomonocytic Leukemia with Central Nervous System Involvement in a Dog
Ilaria Tartari, DVM, Fabio Tocco, DVM, Giorgio Cancedda, DVM, Veronica Angioni, DVM, Marco Podda, DVM, Antonella Gallucci, DVM, PhD, DECVN, EBVS
Treatment Outcomes of Canine Orbital Meningiomas in Seven Cases
Akihiro Uno, DVM, Ryota Iwasaki, DVM, PhD, Takashi Mori, DVM, PhD
Transient Hypoadrenocorticism in a 7-Week-Old Kitten
Alba Planas Vintro, BVM, Linda G. Martin, DVM, MS, DACVECC, Cassidy L. Cordon, DVM, Sabrina N. Hoehne, Dr. med. vet., DACVECC, DECVECC, Elizabeth B. Davidow, DVM, DACVECC